Print

Forest Laboratories, Inc. (FRX) and Almirall to Present Aclidinium Bromide Clinical Data at the American Thoracic Society International Conference  
5/18/2012 10:25:11 AM

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) and Almirall, S.A. (ALM.MC) today announced that they will present aclidinium-related data in 1 poster discussion session and 3 poster presentations at the American Thoracic Society (ATS) International Conference scheduled May 18 - 23 in San Francisco, CA. Positive top-line results from the aclidinium pivotal double-blind placebo-controlled studies were first reported in 2011. Aclidinium bromide is a new, inhaled long-acting antimuscarinic agent currently under review by the FDA for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD).
//-->